NewAmsterdam Pharma Company N.V.

NASDAQ:NAMS

Biotechnology

Healthcare
$19.74 +0.39%

+$0.12 today

Market cap
$2.37B
Beta
0.08
P/E (TTM)
-17.2
EPS (TTM)
-$1.76
52W Low $17.63High $42.21

Volume 1.80M

Average 1.21M

NAMS Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

NewAmsterdam Pharma Company N.V.NASDAQ: NAMS

Net Change in Cash · Q2 FY2026 · quarter ended Jun 2026

Net change in cash declines year over year

Q2 FY2026 net change in cash of $33.44M (cash outflow) fell 81.9% year over year, ahead of the -203.9% change in trailing-twelve-month net change in cash. Sequentially, it rose 3.3% from the prior quarter.

Context

  • Net change in cash amounted to 1246.1% of revenue in FY2025, up 299.6 pp from a year earlier.
  • Net change in cash increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -81.9% holds above the trailing-twelve-month pace of -203.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$33.44M+3.3% QoQ
Last fiscal yearDec 2025
-$280.42M-165.0% YoY
LTMJun 2026
-$138.36M-203.9% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-81.9%——
1 year-165.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
(280.42M) USD
Year-over-year change
-165.0%

Net Change in Cash vs competitors

How NAMS compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -203.9% is the lowest of 9, against a peer median of +60.8%.
  • Net change in cash amounts to 1942.9% of revenue for NAMS, versus a peer median of 158.8%.
NAMS Competitors
Net Change in Cash for NAMS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SEPNSepterna, Inc.LTM Sep 2026$152.87M USD-166.0%—158.8%
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026$138.36M USD-203.9%—1942.9%
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 2026$101.69M USD+133.0%-30.6%7.9%
VKTXViking Therapeutics, Inc.LTM Jun 2026$91.87M USD+1015.5%+138.5%—
DNLIDenali Therapeutics Inc.LTM Jun 2026$60.32M USD-11.4%—1673.8%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$21.64M USD+229.0%+32.2%—
ATHEAlterity Therapeutics LimitedFY2025A$20.52M AUD+754.6%+45.3%377.3%
BIOABioAge Labs, Inc.LTM Mar 2026$15.71M USD-119.6%+70.2%152.3%
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$14.93M USD-90.3%+126.2%—
Peer median (excluding NAMS) —+60.8%+57.8%158.8%

Competitors are the stored peer set for NAMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(41.79M)(22.63M)(176.94M)(241.6M)(203.82M)
Depreciation & Amortization5K9K49K113K220K
Deferred Income Tax00000
Stock-Based Compensation1.24M4.12M24.57M33.62M59.43M
Change in Working Capital4.47M10.37M5.87M(32.67M)(7.94M)
Accounts Receivables0(4.18M)4.03M0(13.28M)
Inventory00000
Accounts Payables6.56M4.81M5.07M(12.95M)4.91M
Other Working Capital(2.09M)9.75M(3.23M)(19.73M)427K
Other Non-Cash Items6.55M18.8M5.23M81.98M4.34M
Operating Cash Flow(29.51M)10.67M(141.22M)(158.56M)(147.78M)
Capital Expenditures(24K)(221K)(24K)(672K)(246K)
Acquisitions (Net)00000
Purchases of Investments000(62.18M)(296.73M)
Sales of Investments0000122.06M
Other Investing Activities00000
Investing Cash Flow(24K)(221K)(24K)(62.85M)(174.92M)
Debt Repayment0747K000
Common Stock Issued84.7M396.95M8.91M645.51M29.52M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0(5.79M)014M0
Financing Cash Flow84.7M391.91M8.91M659.51M29.52M
Effect of Forex Changes(4.68M)5.25M5.05M(6.8M)12.76M
Net Change in Cash50.49M407.6M(127.28M)431.29M(280.42M)
Free Cash Flow(29.54M)10.44M(141.24M)(159.24M)(148.03M)

NewAmsterdam Pharma Company N.V.

NASDAQ:NAMS

Intrinsic Alpha fair value

Locked

Current Price

$19.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.